HRP20180631T1 - Analog mini-gastrina, posebno u uporabi za dijagnozu i/ili liječenje tumora pozitivnog na receptor cck2 - Google Patents

Analog mini-gastrina, posebno u uporabi za dijagnozu i/ili liječenje tumora pozitivnog na receptor cck2

Info

Publication number
HRP20180631T1
HRP20180631T1 HRP20180631TT HRP20180631T HRP20180631T1 HR P20180631 T1 HRP20180631 T1 HR P20180631T1 HR P20180631T T HRP20180631T T HR P20180631TT HR P20180631 T HRP20180631 T HR P20180631T HR P20180631 T1 HRP20180631 T1 HR P20180631T1
Authority
HR
Croatia
Prior art keywords
mini
treatment
receptor positive
positive tumour
cck2 receptor
Prior art date
Application number
HRP20180631TT
Other languages
English (en)
Inventor
Martin Behe
Roger Schibli
Original Assignee
Paul Scherrer Institut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Paul Scherrer Institut filed Critical Paul Scherrer Institut
Publication of HRP20180631T1 publication Critical patent/HRP20180631T1/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/2207Gastrins; Cholecystokinins [CCK]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/008Peptides; Proteins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/13Labelling of peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/57572Gastrin releasing peptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/595Gastrins; Cholecystokinins [CCK]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
HRP20180631TT 2013-11-06 2018-04-19 Analog mini-gastrina, posebno u uporabi za dijagnozu i/ili liječenje tumora pozitivnog na receptor cck2 HRP20180631T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20130191807 EP2870972A1 (en) 2013-11-06 2013-11-06 Mini-gastrin analogue, in particular for use in CCK2 receptor positive tumour diagnosis and/or treatment
EP14795569.4A EP3065764B3 (en) 2013-11-06 2014-10-23 Mini-gastrin analogue, in particular for use in cck2 receptor positive tumour diagnosis and/or treatment
PCT/EP2014/072697 WO2015067473A1 (en) 2013-11-06 2014-10-23 Mini-gastrin analogue, in particular for use in cck2 receptor positive tumour diagnosis and/or treatment

Publications (1)

Publication Number Publication Date
HRP20180631T1 true HRP20180631T1 (hr) 2018-06-01

Family

ID=49518847

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20180631TT HRP20180631T1 (hr) 2013-11-06 2018-04-19 Analog mini-gastrina, posebno u uporabi za dijagnozu i/ili liječenje tumora pozitivnog na receptor cck2

Country Status (18)

Country Link
US (3) US10130724B2 (hr)
EP (2) EP2870972A1 (hr)
JP (3) JP2017501116A (hr)
KR (2) KR20160070160A (hr)
CN (1) CN105705159B (hr)
CY (1) CY1120117T1 (hr)
DK (1) DK3065764T6 (hr)
ES (1) ES2670582T3 (hr)
HR (1) HRP20180631T1 (hr)
HU (1) HUE036943T2 (hr)
LT (1) LT3065764T (hr)
NO (1) NO3065764T3 (hr)
PL (1) PL3065764T6 (hr)
PT (1) PT3065764T (hr)
RS (1) RS57137B1 (hr)
SI (1) SI3065764T1 (hr)
TR (1) TR201802723T4 (hr)
WO (1) WO2015067473A1 (hr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2870972A1 (en) 2013-11-06 2015-05-13 Paul Scherrer Institut Mini-gastrin analogue, in particular for use in CCK2 receptor positive tumour diagnosis and/or treatment
EP3509617A4 (en) * 2016-09-09 2020-05-13 On Target Laboratories, LLC NIR IMAGING AND USE OF THE CHOLECYSTOKININ-2 RECEPTOR
EP3412303A1 (en) * 2017-06-08 2018-12-12 Medizinische Universität Innsbruck Improved pharmacokinetics and cholecystokinin-2 receptor (cck2r) targeting for diagnosis and therapy
EP3459559A1 (en) * 2017-09-21 2019-03-27 Paul Scherrer Institut Minigastrin derivates, in particular for use in cck2 receptor positive tumour diagnosis and/or treatment
US20210261664A1 (en) 2018-06-22 2021-08-26 Junten Bio Co., Ltd. Composition for eliciting infectious immunological tolerance
EP3845652A4 (en) 2018-06-22 2022-04-13 JUNTEN BIO Co., Ltd. ANTIBODIES FOR INDUCING IMMUNTOLERANCE, INDUCED LYMPHOCYTE AND THERAPEUTIC METHOD WITH CELL THERAPY AGENT USING INDUCED LYMPHOCYTE
CN112601531A (zh) 2018-06-22 2021-04-02 顺天生化股份有限公司 使用具有复合状态的细胞混合物诱导免疫耐受的抗体、以及所诱导的淋巴细胞、以及使用所诱导的淋巴细胞的细胞治疗剂和治疗法
EP3868394A1 (en) * 2020-02-20 2021-08-25 Paul Scherrer Institut Mono- and multi-triazolominigastrins for targeting of cck2r-positive neoplasms
WO2021186060A1 (en) 2020-03-20 2021-09-23 Debiopharm International S.A. Radiolabeled gastrin analogue for use in a method of treating and/or imaging cckb receptor positive diseases, in particular pulmonary and extrapulmonary small-cell carcinoma
KR20230044463A (ko) 2020-07-31 2023-04-04 폴 슈레 앙스띠뛰 갈륨-표지된 가스트린 유사체 및 cckb 수용체 양성 종양 또는 암의 영상화 방법에서의 용도
WO2022023541A1 (en) 2020-07-31 2022-02-03 Paul Scherrer Institut Composition comprising a rapalog and a radiolabelled gastrin analogue, in particular for use in the treatment and/or diagnosis of cckb receptor positive cancer or tumors
WO2022023554A1 (en) 2020-07-31 2022-02-03 Paul Scherrer Institut Alpha radiolabeled gastrin analogue and use thereof in methods of treating cckb receptor positive disease
WO2022167057A1 (en) 2021-02-02 2022-08-11 Medizinische Universität Innsbruck Improved cholecystokinin-2 receptor (cck2r) targeting for diagnosis and therapy
KR20240052015A (ko) 2021-09-28 2024-04-22 폴 슈레 앙스띠뛰 Cck2-r을 표적화하는 화합물을 사용한 치료 및/또는 영상화에 대한 암으로 진단된 환자의 반응을 예측하는 방법, 및 암을 선택적으로 치료 및/또는 영상화하는 방법에서 사용하기 위한 화합물

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4650787A (en) 1985-04-25 1987-03-17 Schally Andrew Victor Biologically active octapeptides
EP2870972A1 (en) * 2013-11-06 2015-05-13 Paul Scherrer Institut Mini-gastrin analogue, in particular for use in CCK2 receptor positive tumour diagnosis and/or treatment

Also Published As

Publication number Publication date
DK3065764T3 (en) 2018-03-12
TR201802723T4 (tr) 2018-03-21
US11623014B2 (en) 2023-04-11
HUE036943T2 (hu) 2018-08-28
US20160256580A1 (en) 2016-09-08
PT3065764T (pt) 2018-03-28
CY1120117T1 (el) 2018-12-12
EP2870972A1 (en) 2015-05-13
ES2670582T3 (es) 2018-05-31
RS57137B1 (sr) 2018-07-31
US20210145990A1 (en) 2021-05-20
US10953114B2 (en) 2021-03-23
LT3065764T (lt) 2018-05-10
PL3065764T6 (pl) 2024-01-15
CN105705159B (zh) 2021-02-12
KR20160070160A (ko) 2016-06-17
EP3065764A1 (en) 2016-09-14
NO3065764T3 (hr) 2018-07-21
JP6763069B2 (ja) 2020-09-30
US20190240360A1 (en) 2019-08-08
WO2015067473A1 (en) 2015-05-14
JP6568618B2 (ja) 2019-08-28
SI3065764T1 (en) 2018-05-31
PL3065764T3 (pl) 2018-07-31
EP3065764B3 (en) 2023-10-11
KR102039930B1 (ko) 2019-11-05
EP3065764B1 (en) 2018-02-21
DK3065764T6 (da) 2023-11-06
JP2019218364A (ja) 2019-12-26
KR20180094125A (ko) 2018-08-22
JP2018118996A (ja) 2018-08-02
JP2017501116A (ja) 2017-01-12
CN105705159A (zh) 2016-06-22
US10130724B2 (en) 2018-11-20

Similar Documents

Publication Publication Date Title
HRP20180631T1 (hr) Analog mini-gastrina, posebno u uporabi za dijagnozu i/ili liječenje tumora pozitivnog na receptor cck2
HK1221044A1 (zh) 具有醫學特徵激活的治療裝置
HK1222530A1 (zh) 用於皮膚處理的微閉合及相關方法
HK1222778A1 (zh) 醫用裝置及使用該醫用裝置的方法
EP2967744A4 (en) SKIN TREATMENT DEVICE
HRP20190194T1 (hr) 17a,21-diesteri korteksolona, namijenjeni liječenju tumora
SG11201701035SA (en) Cancer diagnosis and therapy
GB201413357D0 (en) Antibodies for treatment and diagnosis
SG11201700537VA (en) Compounds against ralstonia pickettii for use in the treatment of insulin resistance, and method of diagnosis of insulin resistance
HK1223983A1 (zh) 用於脊柱側凸的分類、診斷和治療的新標記
HK1244821A1 (zh) 用於治療和診斷1型糖尿病中使用的肽
IS9035A (is) Mólýbden efnasambönd til notkunar við meðferð á sýaníðeitrun
EP2949274A4 (en) HEART TREATMENT DEVICE
GB2510477B (en) Formulations for use in the treatment of chronic fatigue and associated conditions, etc
GB201418541D0 (en) Materials for use with general hyperthermia treatment
GB201309498D0 (en) Novel diagnosis and therapy
GB201401806D0 (en) Novel methods for diagnosis and therapy
HUE032883T2 (hu) Poliolok, elõállításuk és alkalmazásuk
IL268265B (en) 3-beta-hydroxy-5-alpha-paragnane-20-one for use in medical treatment
IL244576A0 (en) Anti-vstm5 antibodies and their use for treatment and diagnosis
IL241412A0 (en) Skin care device
IL240303B (en) Skin care device
GB201302884D0 (en) Novel methods for diagnosis and therapy
GB201409978D0 (en) Novel compounds and their use in therapy